• Publications
  • Influence
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
We performed a multicenter survey using a semistructured interview in 1,072 consecutive patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to assess the prevalenceExpand
  • 881
  • 54
  • PDF
The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study
Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential responseExpand
  • 555
  • 48
  • PDF
Validation of the freezing of gait questionnaire in patients with Parkinson's disease
To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each doseExpand
  • 251
  • 35
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either in primary or in secondary care, and are frequently missed during routine consultations. ThereExpand
  • 675
  • 28
  • PDF
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
Levodopa-induced motor complications are a common source of disability for patients with Parkinson's disease. Evidence suggests that motor complications are associated with non-physiological,Expand
  • 434
  • 17
  • PDF
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients
2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's disease (PD). The PD nonmotorExpand
  • 416
  • 15
  • PDF
Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment
This study compares the sensitivity of a Patient Questionnaire versus information gathered by clinicians at a routine clinic visit in recognizing symptoms of wearing‐off in early Parkinson's diseaseExpand
  • 180
  • 12
Ropinirole 24-hour prolonged release
Objective: To evaluate the efficacy of ropinirole 24-hour prolonged release (ropinirole 24-hour) as an adjunct to levodopa in patients with Parkinson disease (PD) and motor fluctuations. Methods: InExpand
  • 204
  • 11
  • PDF
Levodopa in the treatment of Parkinson's disease: Current controversies
Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the “gold standard” against which new agents must be compared. However, there remain two areas ofExpand
  • 332
  • 10
  • PDF
A pharmacological study of cocaine activity in planaria.
Planaria has been proposed as a suitable research model in neurobiology because of its relatively simple organization. Dopaminergic agonists induce in this flatworm typical hyperkinesias that can beExpand
  • 82
  • 9